Q: Peter or Ryan.... The markets have fallen dramatically over the past week and, with oil approaching $95 a barrel, do you think we are slowly moving into correction territory? August traditionally has been one of the worst months for the stock market, if not THE worst. And, if the markets do correct 10%, how easily could 10% become 20% or 30% with stop-loss orders kicking in on the way down? Your comments please.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: your preference between CNQ and TOU.Thanks,ebrahim
Q: re: BA.US Boeing
I am still looking at taking a position. Price continues to fall down another 2% today on extremely high volume. Your last comment mentioned falling price makes valuation that much more attractive.
Would you recommend a "wait and see" attitude or buy at this time?
Thanks for all you do
Gord
I am still looking at taking a position. Price continues to fall down another 2% today on extremely high volume. Your last comment mentioned falling price makes valuation that much more attractive.
Would you recommend a "wait and see" attitude or buy at this time?
Thanks for all you do
Gord
Q: CUS
The market seems to like the latest earnings!? Are they back on track (no pun intended)?
The market seems to like the latest earnings!? Are they back on track (no pun intended)?
Q: Hi 5i,
Can you provide any comment on WSP's earnings? Still a good buy for dividend and growth at this level?
Thanks!
Wayne
Can you provide any comment on WSP's earnings? Still a good buy for dividend and growth at this level?
Thanks!
Wayne
Q: re: SUM ... Solium
7% increase today. Is there specific news responsible? And what are your thoughts moving forward?
Thanks for all you do
Gord
7% increase today. Is there specific news responsible? And what are your thoughts moving forward?
Thanks for all you do
Gord
Q: Hi,
Can you elaborate on your comments on preferring FM over TCK.B at this time? Is it because of the weakness in coal?
Thank you
Can you elaborate on your comments on preferring FM over TCK.B at this time? Is it because of the weakness in coal?
Thank you
Q: Good morning.
What's your assessment of the Cineplex (CGX) results?
My quick read is that results are good to very good, with an increasing dividend.
Time to buy? (I'm guessing that "waiting for a pullback" is a bit of a mug's game with this resilient stock.)
Thanks.
What's your assessment of the Cineplex (CGX) results?
My quick read is that results are good to very good, with an increasing dividend.
Time to buy? (I'm guessing that "waiting for a pullback" is a bit of a mug's game with this resilient stock.)
Thanks.
Q: I am trying to time the exit on HND. I was waiting for $3.60 nat gas. Is this too low and I should sell at a higher price?
Thanks.
Grant
Thanks.
Grant
Q: Good Morning
What is your view with regards to holding General Mills GIS.US and PowerShare Preferred Portfolio E.T.F PGX.US as long term holds in a RRSP.
What is your view with regards to holding General Mills GIS.US and PowerShare Preferred Portfolio E.T.F PGX.US as long term holds in a RRSP.
Q: Good morning Peter
Would you recommend the purchase of Uni-Select at this price level. From last weeks earnings release sales were flat to low growth but the profit per share has been increasing. I think the market is focused on the revenue number and has missed the earnings growth and the increase in the dividend last quarter.
thank you David
Would you recommend the purchase of Uni-Select at this price level. From last weeks earnings release sales were flat to low growth but the profit per share has been increasing. I think the market is focused on the revenue number and has missed the earnings growth and the increase in the dividend last quarter.
thank you David
Q: What is the better buy - Visa V @$211.or MasterCard MA @$75. BNN guests were about equal in their preference.
Perhaps there are other prospects that are better than either. Thank you AWS
Perhaps there are other prospects that are better than either. Thank you AWS
Q: I'm a GIC buyer with extensive experience in writing covered calls, but haven't used that procedure for a while. After a market correction is usually a good time to start buying higher yielding stocks with higher premiums. It's easier to lose a stock to a call rather than watch it go down. Do you have any suggestions on higher yielding stocks with higher yielding premiums to be bought on a correction? In the past I've used BTE,ARX,SLF,SU,HSE,BCE,T,BNS,CM,etc. I'll take the responsibility for the timing.
Another procedure would involve buying quality companies where the sector is out of favour. Recently I've looked at G, AEM, TCK.B and Bad. They have an average premium yield on the second next call (46 days) of about 30%. The DTC yield is about 3.00%. If the stocks go down, I have a higher-than-GIC yield and can hold until the stocks increase and I can start selling calls again. Do you have any suggestions on this type of out of favour stocks. Thanks for your help.
Another procedure would involve buying quality companies where the sector is out of favour. Recently I've looked at G, AEM, TCK.B and Bad. They have an average premium yield on the second next call (46 days) of about 30%. The DTC yield is about 3.00%. If the stocks go down, I have a higher-than-GIC yield and can hold until the stocks increase and I can start selling calls again. Do you have any suggestions on this type of out of favour stocks. Thanks for your help.
Q: Good Morning
What is your view of the new Transalta floating rate pref. for a longer term income holding?
Thanks for your input.
What is your view of the new Transalta floating rate pref. for a longer term income holding?
Thanks for your input.
Q: Peter,
Could you please comment on Element Financial (EFN on TSX). Lost over 6% in the last 5 days.
Thanks,
ZK
Could you please comment on Element Financial (EFN on TSX). Lost over 6% in the last 5 days.
Thanks,
ZK
Q: Hi Peter and Team,
Could you please give your opinion on HWO's current weakness and is it still a good hold or even buy at this point.
Thanks Peter
Could you please give your opinion on HWO's current weakness and is it still a good hold or even buy at this point.
Thanks Peter
Q: Good Morning Peter and Team,
Could you please comment on the Q2 results of Glentel (GLN-TSX). It seems that their Australian acquisition has not gone well at all. Other divisions are doing OK. Do you think that there is any hope for this company going forward or should I just drive on ??? Also what would you replace it with ??? Thank you very much, DL
Could you please comment on the Q2 results of Glentel (GLN-TSX). It seems that their Australian acquisition has not gone well at all. Other divisions are doing OK. Do you think that there is any hope for this company going forward or should I just drive on ??? Also what would you replace it with ??? Thank you very much, DL
Q: I was wondering which stock you would prefer, Stantec or Aecon.
Thanks
Thanks
Q: TOS: you were pretty negative about TOS yesterday. Today Canaccord was positive about the company - not hard as it moved up 35%. Does the latest company report change your mind?
TSO3* (TOS : TSX : $0.97), Net Change: 0.25, % Change: 34.72%, Volume: 509,859
It’s the Final Countdown! TSO3 reported second-quarter results, with revenues growing to $132,179, as compared to $37,255
in the second quarter in 2013. EPS for the quarter came in at a loss of $0.02, in line with consensus estimates. The innovator in
low temperature sterilization technology for medical devices, said the higher sales in 2014 reflect a higher utilization by the
users of the installed base of sterilizers leading to increased sales of consumables, as well as an increase in maintenance and
compatibility testing services. Canaccord Genuity Sustainability Analyst Sara Elford notes that the results were in line with her
estimates and the core tenets of her investment thesis remain as follows: (1) technology platform is game-changing and
applicable across multiple products and end-markets; (2) business model is excellent (very healthy, high-margin recurring
revenue from captive consumable sales based on the in-use installed base); (3) cash balance is sufficient to fund current burn
rate past Q3/15; (4) her confidence in U.S. clearance in 2014 remains very high (5) in her view TSO3 should be an acquisition
target in due course following a successful FDA outcome. In mid-July, TSO3 received an Additional Information Request from
the Agency with respect to its May 2, 2014 submission. Management is very pleased with the bilateral communications so far
and expects to have everything back into the FDA in its final form within a month or two. Elford believes that U.S. clearance
could be a 2014 event, representing an important catalyst for the company.
TSO3* (TOS : TSX : $0.97), Net Change: 0.25, % Change: 34.72%, Volume: 509,859
It’s the Final Countdown! TSO3 reported second-quarter results, with revenues growing to $132,179, as compared to $37,255
in the second quarter in 2013. EPS for the quarter came in at a loss of $0.02, in line with consensus estimates. The innovator in
low temperature sterilization technology for medical devices, said the higher sales in 2014 reflect a higher utilization by the
users of the installed base of sterilizers leading to increased sales of consumables, as well as an increase in maintenance and
compatibility testing services. Canaccord Genuity Sustainability Analyst Sara Elford notes that the results were in line with her
estimates and the core tenets of her investment thesis remain as follows: (1) technology platform is game-changing and
applicable across multiple products and end-markets; (2) business model is excellent (very healthy, high-margin recurring
revenue from captive consumable sales based on the in-use installed base); (3) cash balance is sufficient to fund current burn
rate past Q3/15; (4) her confidence in U.S. clearance in 2014 remains very high (5) in her view TSO3 should be an acquisition
target in due course following a successful FDA outcome. In mid-July, TSO3 received an Additional Information Request from
the Agency with respect to its May 2, 2014 submission. Management is very pleased with the bilateral communications so far
and expects to have everything back into the FDA in its final form within a month or two. Elford believes that U.S. clearance
could be a 2014 event, representing an important catalyst for the company.
Q: we bought rrx at 10.96.what would you do with it buy sell or hold